Advanced Melanoma Clinical Trials in St Louis, Missouri

4 studies are recruiting for advanced melanoma in St Louis, Missouri right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

  1. Memory-Like Natural Killer Cells With Nivolumab and Relatlimab in Advanced or Metastatic Melanoma After Progression on Checkpoint Inhibitors

    This is a Phase 1 open-label, study designed to characterize the safety, tolerability, and preliminary anti-tumor activity of memory-like natural killer cells (ML NK) in combination with nivolumab and relatlimab in subjects with advanced and/or metastatic melanoma. There will be two arms to test th…

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Washington University School of Medicine, St Louis, Missouri
    Run by
    Washington University School of Medicine

    See if you can join NCT05629546 on ClinicalTrials.gov

  2. Safety and Efficacy of EIK1001 in Combo With Pembro Versus Placebo and Pembro as First-Line Therapy in Patients With Advanced Melanoma.

    The study is for patients with advanced melanoma who are eligible for standard therapy with Pembrolizumab.

    Stage
    Phase 2
    Ages
    18 and older
    Site
    Washington University School of Medicine in St. Louis, St Louis, Missouri
    Locations
    107 in total
    Run by
    Eikon Therapeutics

    See if you can join NCT06697301 on ClinicalTrials.gov

  3. Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM)

    The purpose of this study is to evaluate the efficacy and safety of tebentafusp-based regimens, including tebentafusp monotherapy and in combination with anti-PD1 vs investigator choice (including clinical trials of investigational agents, salvage therapy per local standard of care [SoC], best supp…

    Stage
    Phase 3
    Ages
    18 and older
    Site
    Washington University School of Medicine, St Louis, Missouri
    Locations
    82 in total
    Run by
    Immunocore Ltd

    See if you can join NCT05549297 on ClinicalTrials.gov

  4. IMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301)

    This is a phase 3, randomized, controlled study of brenetafusp (IMC-F106C) plus nivolumab compared to standard nivolumab regimens in HLA-A*02:01-positive participants with previously untreated advanced melanoma.

    Stage
    Phase 3
    Ages
    18 and older
    Site
    Washington University School of Medicine, St Louis, Missouri
    Locations
    211 in total
    Run by
    Immunocore Ltd

    See if you can join NCT06112314 on ClinicalTrials.gov

How to read this page. Every study here comes from ClinicalTrials.gov, the public registry that research teams are required to file with. We have summarised each one in plain language and shown where it is running. We have not changed what any study says it is doing.

What TrialBoost is. We help people find research that might suit them, and, if they ask us to, we pass their details to the research team running it. We are not a doctor, a research site, or a study sponsor, and we do not decide who takes part in anything. Joining costs nothing and you can change your mind at any point.

Paid placement. Some studies pay us when someone asks to be connected to them. Those are labelled Sponsored wherever they appear, and they only appear when they match what you were actually looking for.